Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (37)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dimopoulos, M. A.
Right arrow Articles by Alexanian, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimopoulos, M. A.
Right arrow Articles by Alexanian, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 6:49-52, 1995
© 1995 European Society for Medical Oncology

research-article

Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors

M. A. Dimopoulos, D. Weber, K. B. Delasalle, M. Keating and R. Alexanian

Department of Hematology, University of Texas, M.D. Anderson Cancer Center Houston, TX, USA

Correspondence to: Dr. Meleu'os Dimopoulos, 227 Kifissias Avenue, 14561 Kifissia, Athens, Greece

BACKGROUND: Few effective treatments are available for patients with Waldenstrom's macroglobulinemia that is resistant to standard therapies. We assessed the activity of 2-chlorodeoxyadenosine (2CdA) in patients with resistant macroglobulinemia in order to identify those most likely to benefit.

PATIENTS AND METHODS: 2-chlorodeoxyadenosine was given to 46 consecutive patients with Waldenstrom's macroglobulinemia resistant to a combination of an alkylating agent and a glucocorticoid. Two courses were administered to outpatients at a dose of 0.1 mg/kg body weight per day for a 7-day continuous infusion using a portable pump through a central venous catheter. Responding patients were followed without further therapy.

RESULTS: Twenty of 46 patients responded to 2CdA therapy (43%; 95 CI; 29 to 60%) with a significantly higher frequency of benefit among patients with disease relapsing off therapy (78%) or with primary resistant disease within the first year (57%) than in those with later phases of disease (22%). The median survival after treatment was 28 months and the median progression-free survival of responding patients was 12 months. The longest survival was measured in patients with primary refractory disease (projected median 36 months) and the shortest in those with disease in refractory relapse (median 13 months).

CONCLUSION: 2-Chlorodeoxyadenosine is active against macroglobulinemic lymphoma resistant to standard regimens and most effective in patients with disease relapsing off treatment or during the first year of primary refractory disease. Little benefit was observed among patients with later phases of resistant disease who should receive alternative treatments.

2-chlorodeoxyadenosine, treatment, Waldenstrom's macroglobulinemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
I. M. Ghobrial, A. Roccaro, F. Hong, E. Weller, N. Rubin, R. Leduc, M. Rourke, S. Chuma, A. Sacco, X. Jia, et al.
Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia
Clin. Cancer Res., February 1, 2010; 16(3): 1033 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Vijay and M. A. Gertz
Waldenstrom macroglobulinemia
Blood, June 15, 2007; 109(12): 5096 - 5103.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Dimopoulos, R. A. Kyle, A. Anagnostopoulos, and S. P. Treon
Diagnosis and Management of Waldenstrom's Macroglobulinemia
J. Clin. Oncol., March 1, 2005; 23(7): 1564 - 1577.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. I. Chen
Treatment for Waldenstrom's macroglobulinemia
Ann. Onc., April 1, 2004; 15(4): 550 - 558.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. Leblond, V. Levy, F. Maloisel, B. Cazin, J.-P. Fermand, J.-L. Harousseau, L. Remenieras, R. Porcher, M. Gardembas, G. Marit, et al.
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease
Blood, November 1, 2001; 98(9): 2640 - 2644.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Dimopoulos, P. Panayiotidis, L. A. Moulopoulos, P. Sfikakis, and M. Dalakas
Waldenstrom’s Macroglobulinemia: Clinical Features, Complications, and Management
J. Clin. Oncol., January 5, 2000; 18(1): 214 - 214.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. A. Socinski
Single-Agent Paclitaxel in the Treatment of Advanced Non-Small Cell Lung Cancer
Oncologist, October 1, 1999; 4(5): 408 - 416.
[Abstract] [Full Text]

Home page
 The OncologistHome page
C. J. Langer and D. S. Ettinger
The Burgeoning Role of Paclitaxel in Advanced Pulmonary Malignancy
Oncologist, April 1, 1998; 3(2): 67 - 85.
[Abstract] [Full Text]

Home page
 BloodHome page
R. A. Kyle and K. C. Anderson
A Tribute to Jan Gosta Waldenstrom
Blood, June 15, 1997; 89(12): 4245 - 4247.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.